Who Owns Natera Company?

Who Owns Natera?

Ever wondered about the driving forces behind a major player in genetic testing? Understanding who owns Natera is key to grasping its strategic direction and influence in the evolving healthcare landscape. The company's journey from a private startup to a publicly traded entity has significantly shaped its ownership structure.

Natera, Inc., originally founded in 2004, has grown into a leading clinical genetic testing company, with a strong focus on women's health, oncology, and organ health, utilizing its proprietary cell-free DNA technology. As of early 2025, Natera's market capitalization reached approximately $21.6 billion, with 137 million shares outstanding, highlighting its substantial presence in the biotechnology sector. This Natera ownership structure is largely dominated by institutional investors, a common characteristic of established public companies, alongside significant holdings by its founders and executive team.

The Natera company ownership underwent a significant transformation with its Initial Public Offering (IPO) in July 2015. This event transitioned Natera from a privately held company to a publicly traded one, thereby broadening its shareholder base and injecting substantial capital for continued growth and research initiatives. Exploring the Natera stock ownership breakdown reveals a complex interplay of institutional backing, founder influence, and public market participation. For instance, understanding the Natera company founder and ownership dynamics provides insight into the company's foundational vision. The company's commitment to innovation is evident in its development of advanced diagnostic solutions, including its Natera BCG Matrix, which plays a role in its strategic market positioning.

Delving deeper into Natera company ownership information, we find that institutional investors are among the Natera major shareholders. These entities often include large asset management firms and mutual funds that invest on behalf of many individuals. The Natera board of directors also plays a crucial role in overseeing the company's strategic direction, influenced by the various ownership interests. As a publicly traded company, Natera stock ownership is subject to public disclosure, allowing for a transparent view of who controls Natera stock and the overall Natera ownership structure explained. This transparency is vital for investors seeking to understand the Natera company ownership by country and its impact on innovation.

The question of; Who are the largest shareholders of Natera; is central to understanding the company's governance and future trajectory. While specific percentages fluctuate with market activity, the presence of significant institutional ownership alongside founder stakes indicates a stable yet dynamic Natera company ownership. This structure allows Natera to pursue its ambitious goals in genetic testing while remaining accountable to a broad base of stakeholders. For those interested in Natera investor relations contact, information is typically available through the company's official website, facilitating inquiries about Natera stock market capitalization and ownership.

Natera was established in 2004 by Matthew Rabinowitz and Jonathan Sheena. Matthew Rabinowitz, who previously served as Natera's Chief Executive Officer from 2005 to 2019, currently holds the position of Executive Chairman of the board of directors. Jonathan Sheena is the company's Co-Founder and Chief Technology Officer. Rabinowitz's inspiration to found Natera was deeply personal, stemming from a family tragedy, which fueled a vision to transform prenatal medicine.

Initially known as Gene Security Network, the company introduced its first product, the Spectrum preimplantation genetic test, in 2009. This was followed by the Anora miscarriage test in 2010 and the Horizon advanced carrier screening test in 2012. While the specific equity splits or shareholding percentages at the company's inception are not publicly disclosed, the founders' continued leadership roles and board presence suggest their significant, though diluted, foundational influence on Natera's direction and Mission, Vision & Core Values of Natera.

Founding Vision

The founders' core vision was to develop non-invasive genetic tests addressing critical health areas. This ambition was instrumental in attracting initial capital and shaping the company's early strategic path.

Early Product Launches

Natera's early product pipeline included the Spectrum preimplantation genetic test (2009), the Anora miscarriage test (2010), and the Horizon advanced carrier screening test (2012).

Founder Roles

Matthew Rabinowitz serves as Executive Chairman, having previously been CEO. Jonathan Sheena is the Co-Founder and Chief Technology Officer, indicating their ongoing strategic involvement.

Early Funding

Before its IPO, Natera secured approximately $152 million across 10 funding rounds. Key early institutional investors included Sofinnova Investments, Foresite Capital, and Orbimed.

Founder Equity

Specific initial equity splits for the founders are not publicly detailed. However, their sustained leadership roles suggest significant foundational ownership, which has naturally diluted over time.

Venture Capital Agreements

Typical for venture-backed startups, early agreements likely included vesting schedules and buy-sell clauses to align founder interests with long-term company growth, though Natera's specific terms are not public.

Founders and Early Ownership Dynamics

The founding team's commitment and vision were pivotal in Natera's early development. While precise ownership percentages from the outset are not publicly available, the founders' continued executive and board positions underscore their foundational stake. Early institutional investors played a crucial role in providing the capital necessary for product development and market entry, establishing a base of significant Natera stockholders beyond the founders.

• Founders: Matthew Rabinowitz and Jonathan Sheena
• Founding Year: 2004
• Key Early Products: Spectrum, Anora, Horizon
• Early Institutional Investors: Sofinnova Investments, Foresite Capital, Orbimed
• Total Pre-IPO Funding: Approximately $152 million

Complete Natera Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Natera's journey as a publicly traded entity began with its Initial Public Offering (IPO) on July 2, 2015. This pivotal event saw the company list on the Nasdaq Global Market under the ticker 'NTRA,' with an initial share price of $18.00. The IPO successfully raised approximately $180 million, significantly broadening Natera's ownership base by welcoming a diverse array of institutional and retail investors. This transition marked a significant shift in Natera company ownership, moving from a privately held structure to one with widespread public participation.

The current Natera ownership structure is predominantly characterized by a strong presence of institutional investors, indicating significant confidence in the company's future trajectory. As of July 16, 2025, a total of 1296 institutional owners and shareholders have submitted filings with the SEC, collectively holding 160,494,272 shares. This institutional dominance plays a crucial role in shaping the company's strategic direction and financial performance. While institutional stakeholders hold the majority, the founders and key executives of Natera also maintain a notable stake, ensuring their interests remain aligned with the company's long-term success. Understanding this Natera stock ownership breakdown is key for anyone looking into Natera company ownership.

Natera's Major Shareholders

Institutional investors are the primary holders of Natera stock, reflecting broad market confidence. Key players include The Vanguard Group and BlackRock, among others.

• The Vanguard Group, Inc. is a significant Natera stockholder.
• BlackRock, Inc. also holds a substantial portion of Natera company ownership.
• Other major institutional investors include ARK Investment Management LLC and FMR LLC.
• Founders and executives also maintain important stakes in the company.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Natera company's Board of Directors is instrumental in guiding its strategic direction and corporate governance. As of early 2025, the board includes key figures such as Matthew Rabinowitz, the Executive Chairman of the Board and a co-founder, who significantly influences the company's strategic path. Steve Chapman holds the position of Chief Executive Officer and also sits on the board. Monica Bertagnolli rejoined the board in March 2025, bringing her expertise, while Roy Baynes has been a director since July 2018. Rowan Chapman has also served as a director since August 2019. This diverse composition is designed to incorporate the perspectives of major shareholders, the founders' vision, and independent insights essential for effective oversight.

Natera operates under a standard one-share-one-vote system, a common practice for publicly traded entities. This structure means that each share of common stock grants its holder a single vote on matters presented to shareholders, including director elections and major corporate decisions. There are no publicly disclosed dual-class share structures or special voting rights that would grant any single entity disproportionate control. This ensures that voting power directly correlates with the number of shares owned, promoting a fair distribution of influence among Natera stockholders. As of April 15, 2024, there were 123,241,550 outstanding shares of common stock eligible to vote. While significant institutional investors can exert influence due to their large holdings, the fundamental voting structure ensures that ownership stake dictates voting power. Recent history has not shown major proxy battles or activist campaigns significantly altering Natera's decision-making processes.

Understanding the Natera ownership structure and the influence of its board is key for investors looking to grasp the company's direction. The one-share-one-vote principle ensures that Natera stockholders have a direct say in corporate matters, proportional to their investment. This system, along with the board's composition, aims to foster responsible governance and strategic growth, even as the company navigates a competitive Competitors Landscape of Natera.

Natera's Governance and Voting Power

Natera's governance is anchored by its Board of Directors, who oversee the company's strategic initiatives. The voting power within the company is distributed based on a straightforward one-share-one-vote principle.

• Board members bring diverse expertise in healthcare, finance, and technology.
• Voting power is directly tied to the number of common shares held.
• No dual-class shares or special voting rights have been publicly reported.
• As of April 15, 2024, 123,241,550 shares were outstanding and entitled to vote.

Natera Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Natera's ownership landscape has seen notable shifts in the past few years, significantly influenced by strategic moves and financial performance. A key event was the acquisition of certain reproductive health assets from Invitae in January 2024. This transaction, involving an initial payment of $10 million and potential milestone payments totaling up to $42.5 million, was designed to bolster Natera's presence in women's health and broaden its genetic testing capabilities. This strategic acquisition is anticipated to add between $20 million and $40 million to Natera's business.

Financially, the company has demonstrated strong growth. For the entirety of 2024, Natera reported total revenues of $1,696.9 million, marking a substantial increase of 56.7% from the $1,082.6 million recorded in 2023. Product revenues, largely driven by tests such as Signatera, Panorama, and HCS, reached $1,685.1 million in 2024. The company processed approximately 3.1 million tests in 2024, an increase from 2.5 million tests in the previous year. As of March 31, 2025, Natera had approximately 135,932,000 shares of common stock outstanding, up from 132,646,000 shares at the close of 2024. This growth trajectory has also been reflected in Natera's updated full-year 2025 revenue guidance, which was raised to a range of $1.94 billion to $2.02 billion, indicating expected continued expansion and market penetration, particularly within the oncology sector.

Insider trading activity shows continued involvement from key personnel. Co-founder Matthew Rabinowitz has engaged in share transactions, including sales in June and March 2025. Jonathan Sheena, also a co-founder and director, sold 3,070 shares on July 16, 2025, in accordance with a Rule 10b5-1 trading plan. These actions are typical for executives managing their personal investments. A significant trend observed is the increasing institutional ownership, which rose from 92.49% to 96.32% between February and March 2025. This growing concentration of holdings by large asset managers highlights a broader trend of institutional confidence in established biotechnology firms. For those interested in the company's journey, a Brief History of Natera provides further context.

Institutional Investor Growth

Institutional ownership of Natera shares saw a significant increase from 92.49% to 96.32% between February and March 2025. This trend indicates growing confidence from large asset managers in the company's prospects. Such consolidation often reflects a positive outlook on the company's market position and future performance.

Strategic Acquisition Impact

The acquisition of reproductive health assets from Invitae in January 2024 was a key development for Natera. This move aimed to strengthen its position in women's health and expand its genetic testing services. The transaction is expected to contribute significantly to Natera's business book.

Financial Performance Highlights

Natera reported robust financial growth, with total revenues increasing by 56.7% to $1,696.9 million in 2024. Product revenues, primarily from key tests, accounted for the majority of this revenue. The company also processed a higher volume of tests in 2024 compared to 2023.

Insider Activity and Guidance

Key figures within Natera, including co-founders, have been involved in share transactions, which are standard for executives managing their portfolios. The company has also raised its full-year 2025 revenue guidance, signaling anticipated continued growth and market penetration.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE